Immunologic Factor
Ustekinumab
An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to... more
Brand Names:
Stelara
May Treat:
Group:
Antibodies, Monoclonal, Humanized
Mechanism:
Interleukin-12 Antagonists; Interleukin-23 Antagonists
More Information:
Medscape
Stelara (ustekinumab) dosing, indications, interactions, adverse effects, and more.
Viewing results
1 - 10 of 837,000 (0.26 seconds)
-
Ustekinumab injection is used to treat moderate to severe plaque psoriasis (skin disease in which red, scaly patches form on some areas of the body) in ...
-
USES: Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or certain bowel conditions (Crohn's disease, ulcerative ...
-
Feb 6, 2021 ... We aimed to compare the efficacy and safety of bimekizumab with placebo and ustekinumab in patients with moderate to severe plaque psoriasis ...
-
Oct 18, 2012 ... Background In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and ...
-
Jan 28, 2021 ... How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Ana ...
-
Oct 1, 2015 ... BackgroundEarly clinical studies suggested that the anti–interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the ...
-
Ustekinumab is a targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, ...
-
Sep 9, 2020 ... Importance Ustekinumab, a monoclonal antibody targeting interleukin 12/23p40 (IL-12/23p40), is effective in the treatment of moderate to severe ...
-
This real-world experience on ustekinumab therapy demonstrates a difference in mucosal healing rates between ileum-dominant and colonic CD. Numerically, there ...
-
Mar 27, 2019 ... This cohort study compares the risk of developing atrial fibrillation or major adverse cardiovascular events associated with ustekinumab vs ...